Pregnancy: The safety of Neupogen has not been established in pregnant women. There are reports in the literature where the transplacental passage of filgrastim in pregnant women has been demonstrated (see Pharmacology: Toxicology: Teratogenicity under Actions). Studies in animals have shown reproductive toxicity. In pregnancy, the possible risk of Neupogen use to the fetus must be weighed against the expected therapeutic benefit.
Nursing Mothers: It is not known whether Neupogen is excreted in human milk. Neupogen is not recommended for use in nursing women.